{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:27:34Z","timestamp":1793917654195,"version":"4.8.0"},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Acne\u2010induced hyperpigmentation (AIH) may accompany acne vulgaris (AV) inflammation in all skin phototypes. Trifarotene has shown depigmenting properties in vivo. This study evaluated trifarotene plus skincare because it is increasingly recognized that holistic AV management should include skincare and treatments.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This is a phase IV double\u2010blind, parallel\u2010group study of patients (13\u201335\u2009years) with moderate AV and AIH treated with trifarotene (\n N<\/jats:italic>\n \u2009=\u200960) or vehicle (\n N<\/jats:italic>\n \u2009=\u200963) plus skincare regimen (moisturizer, cleanser, and sunscreen) for 24\u2009weeks. Assessments included the AIH overall disease severity (ODS) score, post\u2010AV hyperpigmentation index (PAHPI), exit interviews, photography, and acne assessments. Standard safety assessments were included.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Trifarotene 50\u2009\u03bcg\/g cream improved significantly from baseline in ODS score versus vehicle (\u22121.6 vs. \u22121.1,\n P<\/jats:italic>\n \u2009=\u20090.03) at Week 12, but scores were comparable between groups at Week 24 (primary endpoint). Trifarotene had a better reduction in PAHPI score at Week 24 (\u221218.9% vs. \u221211.3% vehicle,\n P<\/jats:italic>\n \u2009<\u20090.01). Lesion count reductions were higher with trifarotene at Week 12 versus vehicle (\n P<\/jats:italic>\n \u2009<\u20090.001) and at Week 24 (\n P<\/jats:italic>\n \u2009<\u20090.05), as were IGA success rates versus vehicle at Weeks 12 (\n P<\/jats:italic>\n \u2009<\u20090.05) and 24 (\n P<\/jats:italic>\n \u2009<\u20090.05). Patients agreed that the skincare regimen contributed to less irritation, making treatment adherence easier. Photography showed improvements in pigmentation and erythema across all skin types. AEs were more common in the vehicle group versus trifarotene (30.2 vs. 16.7%, respectively).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In all skin phototypes, there was more rapid improvement in the ODS and PAHPI scores with trifarotene by Weeks 12 and 24, respectively. The combination of trifarotene and skincare correlated with high patient satisfaction and adherence to the treatment protocol.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ijd.17189","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T23:34:51Z","timestamp":1714433691000},"page":"806-815","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Importance of treating acne sequelae in skin of color: 6\u2010month phase\n IV<\/scp>\n study of trifarotene with an appropriate skincare routine including\n UV<\/scp>\n protection in acne\u2010induced post\u2010inflammatory hyperpigmentation"],"prefix":"10.1111","volume":"63","author":[{"given":"Andrew","family":"Alexis","sequence":"first","affiliation":[{"name":"Department of Dermatology Weill Cornell Medical College New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Q.","family":"Del Rosso","sequence":"additional","affiliation":[{"name":"JDR Dermatology Research Las Vegas NV USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Forman","sequence":"additional","affiliation":[{"name":"ForCare Medical Center Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[{"name":"Hospital de Manises Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Browning","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Laquer","sequence":"additional","affiliation":[{"name":"First OC Dermatology Research Inc. Fountain Valley CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[{"name":"Innovative Dermatology Plano TX USA"},{"name":"Department of Dermatology The University of Texas Southwestern Medical Center Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"York","sequence":"additional","affiliation":[{"name":"Galderma Laboratories, LP Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-1563","authenticated-orcid":false,"given":"Rajeev","family":"Chavda","sequence":"additional","affiliation":[{"name":"Galderma Lausanne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Dhawan","sequence":"additional","affiliation":[{"name":"Center for Dermatology Clinical Research, Inc. Fremont CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Y.","family":"Moore","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center Dallas TX USA"},{"name":"Arlington Research Center Arlington TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein\u2010Gold","sequence":"additional","affiliation":[{"name":"Henry Ford Medical Center West Bloomfield MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-59715-2"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad026"},{"key":"e_1_2_6_4_1","volume-title":"Andrews' diseases of the skin: clinical atlas","author":"James WD","year":"2018"},{"key":"e_1_2_6_5_1","first-page":"22","article-title":"Understanding the burden of adult female acne","volume":"7","author":"Tanghetti EA","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12757"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13263"},{"key":"e_1_2_6_8_1","first-page":"20","article-title":"Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color","volume":"3","author":"Davis EC","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00633-4"},{"key":"e_1_2_6_10_1","first-page":"24","article-title":"A review of acne in ethnic skin: pathogenesis, clinical manifestations, and management strategies","volume":"3","author":"Davis EC","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/JCAS.JCAS_171_18"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.06.006"},{"key":"e_1_2_6_13_1","first-page":"19","article-title":"Considerations for treating acne in ethnic skin","volume":"76","author":"Callender VD","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.035"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb02566.x"},{"key":"e_1_2_6_16_1","first-page":"33","article-title":"Concomitant therapy for acne in patients with skin of color: a case\u2010based approach","volume":"21","author":"Alexis AF","year":"2009","journal-title":"Dermatol Nurs"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16719"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15794"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.044"},{"key":"e_1_2_6_20_1","first-page":"48","article-title":"Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients","volume":"68","author":"Jacyk WK","year":"2001","journal-title":"Cutis"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199305203282002"},{"key":"e_1_2_6_22_1","first-page":"45","article-title":"Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double\u2010blind, randomized, vehicle\u2010controlled study","volume":"77","author":"Grimes P","year":"2006","journal-title":"Cutis"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.02.053"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00643-2"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00788-w"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2018.3367"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15519"},{"key":"e_1_2_6_28_1","first-page":"25","article-title":"Efficacy and safety of clindamycin phosphate 1.2% and tretinoin 0.025% gel for the treatment of acne and acne\u2010induced post\u2010inflammatory hyperpigmentation in patients with skin of color","volume":"5","author":"Callender VD","year":"2012","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T06:18:09Z","timestamp":1726035489000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.17189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/ijd.17189"],"URL":"https:\/\/doi.org\/10.1111\/ijd.17189","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"2024-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}